Atogepant, Placebo for Atogepant
M23-712
Phase 3 small_molecule active
Quick answer
Atogepant, Placebo for Atogepant for Chronic Migraine is a Phase 3 program (small_molecule) at AbbVie Deutschland GmbH & Co. KG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AbbVie Deutschland GmbH & Co. KG
- Indication
- Chronic Migraine
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active